
Conference Coverage
about 2 hours ago
Olanzapine/Samidorphan Tied to Longer Persistence in Schizophreniaabout 4 hours ago
IDWeek 2026 Recap: Care Gaps and Value of Collaborationabout 5 hours ago
Povetacicept Cuts Proteinuria in IgAN: Richard Lafayette, MD, FACPabout 7 hours ago
PCOC Recap: Seven Leaders Define Patient-Centered Oncology Careabout 9 hours ago
Payers, Health Systems Should Look Beyond the ICU: CHEST 2026 RecapLatest Content

The DTC GLP-1 Boom Solved Access. Can It Solve Adherence?

Olanzapine/Samidorphan Tied to Longer Persistence in Schizophrenia

Review Finds MS Is an Underrecognized Cause of Acute Vertigo

FAQ: Ways Health Plans Can Assist Members in Medicaid Redetermination

Youths With Depression Face Higher Odds of Prescription Drug Misuse

Shorts










Center on Health Equity & Access
All News

University of Virginia Health is tracking efgartigimod durability in generalized myasthenia gravis and how pharmacists help patients get past barriers.

NCCN now lists the brain-penetrant ROS1 inhibitor after progression on earlier TKIs, including as a preferred option for symptomatic brain progression.

KFF finds 4.3 million Medicare beneficiaries will lose their MA or stand-alone Part D plans at the end of 2026, as PDP options keep shrinking.

Anti-CGRP antibody exposure near conception was linked to higher spontaneous abortion risk in migraine, while propranolol was not, a cohort study found.

Combined MRI and ultrasound raised sensitivity for bowel and uterosacral ligament endometriosis but reduced specificity in a prospective cohort study.

The Cambridge Multimorbidity Score was adapted to ICD-10 and demonstrated better predictive performance than the Charlson Comorbidity Index in German primary care claims data.

Asia-Pacific Delphi Consensus updates alopecia areata clinical guidelines for trichoscopy, SALT Score severity, and first-line JAK inhibitors.

Biomarker testing, treatment sequencing, drug delivery, and rural access barriers were examined during an IVBM event in Salt Lake City.

Experts spot idiopathic hypersomnia when tests miss it, using symptom scales, targeted questions, wearables, and shared treatment choices.

At an AJMC® Stakeholder Interchange in New York, New York, leukemia specialists agreed that menin inhibitors fill a real gap in relapsed/refractory acute myeloid leukemia, but said that slow molecular testing, formulary rules, and thin community infrastructure still determine which patients get them and how fast.



























